Dear Healthcare Provider Letter Issued on Use of Lopinavir/Ritonavir in Children
On August 13, the Food and Drug Administration (FDA) announced that a Dear Healthcare Provider letter had been issued regarding dosing of Kaletra (lopinavir/ritonavir) oral solution in children. Recently, an infant was accidentally given 10 times the appropriate amount of solution and subsequently died as a result of the overdose. Healthcare providers are cautioned that Kaletra oral solution is highly concentrated and that infants should receive no more than 5 ml per dose in most cases. For full details, read the official FDA press release.
More information is available on lopinavir/ritonavir and pediatric HIV:
- AIDSinfo: Pediatric Treatment Guidelines
- AIDSinfo: Lopinavir/ritonavir drug fact sheet
- AIDSinfo: Lopinavir/ritonavir clinical trials
- FDA: Drugs Used in the Treatment of Pediatric HIV Infection
- Health Resources and Services Administration: Pediatric HIV/AIDS in the United States
HRSA Awards $70.6 Million to Fight HIV/AIDS in At-Risk Communities
The Health Resources and Services Administration (HRSA) has awarded $70.6 million in funding to address the impact of HIV/AIDS on women and racial and ethnic minorities. The funds are granted under the Ryan White HIV/AIDS Program. Of the total funding, $48.8 million will be used as part of the Minority AIDS Initiative, and $21.8 million will support HIV/AIDS care for women and youth across the country. Funding details and allocations can be found at the HRSA Newsroom.
More information on these programs is also available:
- HRSA HIV/AIDS Bureau: The Ryan White HIV/AIDS Program
- Office of Minority Health: Minority AIDS Initiative
- National Institute of Allergy and Infectious Diseases (NIAID): HIV Infection in Minority Populations and HIV Infection in Women fact sheets
- AIDSinfo: HIV/AIDS Health Topics for Minorities and Women
